Pierre-Edouard GRILLET

Dr. Pierre-Edouard GRILLET

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
PGPierre-Edouard GRILLET
Pierre-Edouard GRILLET
EDElodie Desplanche
Elodie Desplanche
QWQuentin Wynands
Quentin Wynands
Fares GouziFares Gouzi
Fares Gouzi
PBPatrice Bideaux
Patrice Bideaux
OCOlivier Cazorla
Olivier Cazorla
Chronic obstructive pulmonary disease (COPD) is a clinical entity of increasing significance. COPD involves abnormalities of the airways and, in emphysema, parenchymal pulmonary destruction. Cardiovascular disease has emerged as a significant comorbidity to COPD. Heart failure with preserved ejection fraction (HFpEF) appears to be particularly associated with COPD-emphysema. Traditional treatments have shown limited efficacy in improving COPD-associated HFpEF. This lack of therapeutic efficacy highlights the need to identify potential mechanisms that link COPD-emphysema to HFpEF. Therefore, we aimed to study the delayed cardiac physiological impacts in a rat model with acute exacerbated emphysema. Emphysema was induced by four weekly 4 units elastase (ELA) intratracheal pulmonary instillations and exacerbation by one final additional lipolysaccharide (LPS) instillation in male Wistar rats. At 5 weeks after the ELA and LPS exposure, in vivo and ex vivo pulmonary and cardiac measurements were performed. Experimental exacerbated emphysema resulted in decreased pulmonary function and exercise intolerance. Histological analysis revealed parenchymal pulmonary destruction without signs of inflammation or cardiac fibrosis. In vivo cardiac functional analysis revealed diastolic dysfunction and tachycardia. Ex vivo analysis revealed a cellular cardiomyopathy with decreased myofilament Ca2+ sensitivity, cross-bridge cycling kinetics, and increased adrenergic PKA (protein kinase A)-dependent phosphorylation of troponin-I. Experimental exacerbated emphysema was associated with exercise intolerance that appeared to be secondary to increased β-adrenergic tone and subsequent cardiac myofilament dysfunction. A β1-receptor antagonist treatment (bisoprolol) started 24 hours after ELA-LPS instillation prevented in vivo and ex vivo diastolic dysfunction. These results suggest that novel treatment strategies targeted to the cardiac myofilament may be beneficial to combat exacerbated emphysema–associated HFpEF.

22 July 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
MYMarc Yehya
Marc Yehya
DBDoria Boulghobra
Doria Boulghobra
PGPierre-Edouard GRILLET
Pierre-Edouard GRILLET
PFPablo Rafael Fleitas-Paniagua
Pablo Rafael Fleitas-Paniagua
PBPatrice Bideaux
Patrice Bideaux
OCOlivier Cazorla
Olivier Cazorla
Muscle fatigue is a common symptom induced by exercise. A reversible loss of muscle force is observed with variable rates of recovery depending on the causes or underlying mechanisms. It can not only affect locomotion muscles, but can also affect the heart, in particular after intense prolonged exercise such as marathons and ultra-triathlons. The goal of our study was to explore the effect of four different natural extracts with recognized antioxidant properties on the contractile function of skeletal (locomotion) and cardiac muscles after a prolonged exhausting exercise. Male Wistar rats performed a bout of exhausting exercise on a treadmill for about 2.5 h and were compared to sedentary animals. Some rats received oral treatment of a natural extract (rosemary, buckwheat, Powergrape®, or rapeseed) or the placebo 24 h and 1 h before exercise. Experiments were performed 30 min after the race and after 7 days of recovery. All natural extracts had protective effects both in cardiac and skeletal muscles. The extent of protection was different depending on muscle type and the duration post-exercise (just after and after one-week recovery), including antiarrhythmic effect and anti-diastolic dysfunction for the heart, and faster recovery of contractility for the skeletal muscles. Moreover, the muscular protective effect varied between natural extracts. Our study shows that an acute antioxidant supplementation can protect against acute abnormal endogenous ROS toxicity, induced here by prolonged exhausting exercise.

29 April 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
PGPierre-Edouard GRILLET
Pierre-Edouard GRILLET
SBStéphanie Badiou
Stéphanie Badiou
Karen LambertKaren Lambert
Karen Lambert
TSThibault Sutra
Thibault Sutra
MPMaëlle Plawecki
Maëlle Plawecki
JCJean Paul Cristol
Jean Paul Cristol
The screening of skeletal muscle diseases constitutes an unresolved challenge. Currently, exercise tests or plasmatic tests alone have shown limited performance in the screening of subjects with an increased risk of muscle oxidative metabolism impairment. Intensity-adjusted energy substrate levels of lactate (La), pyruvate (Pyr), β-hydroxybutyrate (BOH) and acetoacetate (AA) during a cardiopulmonary exercise test (CPET) could constitute alternative valid biomarkers to select “at-risk” patients, requiring the gold-standard diagnosis procedure through muscle biopsy. Thus, we aimed to test: (1) the validity of the V’O2-adjusted La, Pyr, BOH and AA during a CPET for the assessment of the muscle oxidative metabolism (exercise and mitochondrial respiration parameters); and (2) the discriminative value of the V’O2-adjusted energy and redox markers, as well as five other V’O2-adjusted TCA cycle-related metabolites, between healthy subjects, subjects with muscle complaints and muscle disease patients. Two hundred and thirty subjects with muscle complaints without diagnosis, nine patients with a diagnosed muscle disease and ten healthy subjects performed a CPET with blood assessments at rest, at the estimated 1st ventilatory threshold and at the maximal intensity. Twelve subjects with muscle complaints presenting a severe alteration of their profile underwent a muscle biopsy. The V’O2-adjusted plasma levels of La, Pyr, BOH and AA, and their respective ratios showed significant correlations with functional and muscle fiber mitochondrial respiration parameters. Differences in exercise V’O2-adjusted La/Pyr, BOH, AA and BOH/AA were observed between healthy subjects, subjects with muscle complaints without diagnosis and muscle disease patients. The energy substrate and redox blood profile of complaining subjects with severe exercise intolerance matched the blood profile of muscle disease patients. Adding five tricarboxylic acid cycle intermediates did not improve the discriminative value of the intensity-adjusted energy and redox markers. The V’O2-adjusted La, Pyr, BOH, AA and their respective ratios constitute valid muscle biomarkers that reveal similar blunted adaptations in muscle disease patients and in subjects with muscle complaints and severe exercise intolerance. A targeted metabolomic approach to improve the screening of “at-risk” patients is discussed.

Verified
Journal Article
Open access
PDF file
EDElodie Desplanche
Elodie Desplanche
PGPierre-Edouard GRILLET
Pierre-Edouard GRILLET
QWQuentin Wynands
Quentin Wynands
PBPatrice Bideaux
Patrice Bideaux
LALaurie Alburquerque
Laurie Alburquerque
AVAnne Virsolvy
Anne Virsolvy
Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease involving airway closure and parenchyma destruction (emphysema). Cardiovascular diseases are the main causes of morbi-mortality in COPD and, in particular, hypertension and heart failure with preserved ejection fraction (HFpEF). However, no mechanistic link has currently been established between the onset of COPD, elevated blood pressure (BP) and systemic vascular impairment (endothelial dysfunction). Thus, we aimed to characterize BP and vascular function and remodeling in a rat model of exacerbated emphysema focusing on the role of sympathetic hyperactivity. Emphysema was induced in male Wistar rats by four weekly pulmonary instillations of elastase (4UI) and exacerbation by a single dose of lipopolysaccharides (LPS). Five weeks following the last instillation, in vivo and ex vivo cardiac and vascular functions were investigated. Exacerbated emphysema induced cardiac dysfunction (HFpEF) and a BP increase in this COPD model. We observed vasomotor changes and hypotrophic remodeling of the aorta without endothelial dysfunction. Indeed, changes in contractile and vasorelaxant properties, though endothelium-dependent, were pro-relaxant and NO-independent. A β1-receptor antagonist (bisoprolol) prevented HFpEF and vascular adaptations, while the effect on BP increase was partial. Endothelial dysfunction would not trigger hypertension and HFpEF in COPD. Vascular changes appeared as an adaptation to the increased BP. The preventing effect of bisoprolol revealed a pivotal role of sympathetic hyperactivation in BP elevation. The mechanistic link between HFpEF, cardiac sympathetic activation and BP deserves further studies in this exacerbated-emphysema model, as well as in COPD patients.

1 July 2026 in Journal of Applied Physiology
Verified
Journal Article
Open access
EDElodie Desplanche
Elodie Desplanche
PGPierre-Edouard GRILLET
Pierre-Edouard GRILLET
LALaurie Alburquerque
Laurie Alburquerque
PPPascal Pomiès
Pascal Pomiès
EPEmilie Passerieux
Emilie Passerieux
AVAnne Virsolvy
Anne Virsolvy
Chronic obstructive pulmonary disease (COPD) is linked to cardiovascular comorbidities, but the vascular benefits of exercise remain uncertain. In an elastase-LPS rat model of COPD with preexisting vascular adaptations, aerobic training improves exercise capacity and lowers blood pressure but does not further enhance vascular reactivity or angiogenesis. Pathological vascular adaptations in COPD may interfere with the vascular benefits of aerobic training.

7 April 2026
Verified
Thesis
Closed access
PGPierre-Edouard GRILLET
Pierre-Edouard GRILLET
La Broncho pneumopathie chronique obstructive ou BPCO est un enjeu majeur de santé publique et représente la 3ème cause de mortalité dans le monde. Cette pathologie chronique regroupe en son sein le plus souvent une anomalie de voies aériennes supérieures associée à un emphysème respiratoire dont la cause principale est l’exposition aux polluants atmosphériques et à la fumée de cigarette. De nombreuses comorbidités sont associées à la BPCO (obésité, syndrome métabolique, diabète…), dont les maladies cardiovasculaires représentent une part importante, notamment, des anomalies de la fonction diastolique, c’est-à-dire la phase de relaxation du cœur sont fréquemment remarquées. La dysfonction diastolique et plus précisément, l’insuffisance cardiaque à fraction d’éjection préservée (HFpEF) partage des mécanismes physiopathologiques communs à la BPCO (dysfonction endothéliale, stress oxydant, inflammation…) mais à ce jour, peu de choses sont connues sur les mécanismes amenant de l’un à l’autre. L’objectif de ce travail de thèse a été de mettre en place un modèle animal résumant les atteintes présentes chez le patient BPCO par création d’un emphysème pulmonaire induit par l’élastase ainsi qu’une atteinte de type exacerbation par instillation pulmonaire de LPS, un constituant de la paroi bactérienne. Dans un second temps, le but a été la caractérisation des altérations fonctionnelles cardiaques induites par le modèle sur le plan physiologique et sur le plan cellulaire pour enfin amener une intervention thérapeutique pharmacologique.Ce modèle a permis la création d’un phénotype de BPCO-emphysème avec l’apparition d’une intolérance à l’effort chez les animaux traités vis-à-vis des contrôles, associée à une insuffisance cardiaque à fraction d’éjection préservée. Cette dysfonction est complétée par un remodelage cardiaque touchant les oreillettes comme le ventricule droit. Les atteintes diastoliques droites et gauches semble être en relation avec une élévation du tonus -adrénergique aboutissant à une altération des cardiomyocytes et une dysfonction du myofilament en lien avec des modifications post-traductionnelles induites par la PKA.La mise en place d’une thérapie par -bloqueur a permis de restaurer de nombreuses atteintes mise en évidence. Les résultats de ces travaux suggèrent qu’une nouvelle approche thérapeutique autour des voies -adrénergiques, et notamment ciblant des différents sous-types de récepteurs pourrait être bénéfique dans le cadre du traitement de l’insuffisance cardiaque à fraction d’éjection préservée spécifique au patient BPCO.